HeartRhythm

MARCH 31, 2025

Pulmonary vein isolation (PVI) is an effective treatment for atrial fibrillation (AF). Baseline heart rate (HR) in normal sinus rhythm (NSR) has been observed to increase after PVI, thought to be due to modification of ganglionated plexi during PVI.

Pulmonary 40

Pulmonary Atrial Fibrillation Arrhythmia 40

HeartRhythm

MARCH 31, 2025

The AP Fontan operation and the total cavo-pulmonary connection (TCPC) have revolutionised the surgical treatment of patients with functionally univentricular hearts. However, post-surgical arrhythmias contribute considerably to morbidity and mortality and can be difficult to manage.

Arrhythmia 40

Arrhythmia Technology Ablation Pulmonary 40

HeartRhythm

JANUARY 27, 2025

The results of pulmonary vein isolation are limited by arrhythmia recurrence, which is most often due to a failure to effectuate a durable contiguous circumferential transmural lesion around the pulmonary vein (PV) ostia.

Pulmonary 40

Pulmonary Ablation Arrhythmia 40

HeartRhythm

APRIL 30, 2024

Low voltage area (LVA) and low conduction velocity (CV) are promising risk factors to identify patients with abnormal atrial substrate at a high risk of atrial fibrillation (AF) recurrence following pulmonary vein isolation (PVI).

Pulmonary 40

Pulmonary Atrial Fibrillation Arrhythmia Risk Factors 40

Journal of the American Heart Association

APRIL 10, 2025

BackgroundAtrial dysfunction is a risk factor for atrial arrhythmia and can be detected by atrial strain imaging in patients with biventricular circulation. Newonset and recurrent atrial arrhythmias were ascertained from baseline encounter to last followup.

Arrhythmia 40

Arrhythmia Risk Factors Pulmonary Circulation 40

HeartRhythm

MARCH 31, 2025

Whilst pulmonary vein isolation (PVI) is the key endpoint for catheter ablation therapy for atrial fibrillation (AF), it is unknown whether adjunctive carinal ablation impacts outcome beyond achieving first pass isolation.

Atrial Fibrillation 40

Atrial Fibrillation Pulmonary Ablation Arrhythmia 40

HeartRhythm

AUGUST 27, 2024

Figure 1 shows the chest radiograph of the first patient diagnosed with amiodarone pulmonary toxicity back in 1978.1 Amiodarone had been in use for the treatment of cardiac arrhythmias for more than a decade by the time we first identified a potential association of amiodarone therapy and pulmonary toxicity.1

Pulmonary 40

Pulmonary Myocardial Infarction Arrhythmia 40

HeartRhythm

APRIL 30, 2024

Atrial arrhythmias (AA) are common in patients with pulmonary disease and various cancers. However, the association between AA and non-small cell lung cancer (NSCLC), and the impact of AA on overall clinical outcome in patients with NSCLC are not well-known.

Cancer 40

Cancer Arrhythmia Pulmonary Outcomes 40

HeartRhythm

APRIL 30, 2024

Recurrent arrhythmia post PVI is most often secondary to pulmonary vein (PV) reconnections. The evidence on use of adenosine triphosphate (ATP) vs. isoproterenol (ISO) during PVI to reduce recurrence of arrhythmia is conflicting.

Arrhythmia 40

Arrhythmia Pulmonary 40

HeartRhythm

JANUARY 7, 2025

Patients with D-transposition of the great arteries (D-TGA) palliated with atrial switch often develop atrial arrhythmias (AA) requiring pulmonary venous atrium (PVA) access for ablation, which can be achieved via retrograde aortic approach (RAA) or trans-baffle access (TBA).13

Arrhythmia 45

Arrhythmia Aortic Ablation Pulmonary 45

HeartRhythm

MARCH 31, 2025

Despite advances in treatment of atrial fibrillation (AF) with pulmonary vein isolation (PVI), AF recurrence remains a challenge. High tx burden pre-PVI may lead to difficulty maintaining arrhythmia freedom post-PVI.

Atrial Fibrillation 40

Atrial Fibrillation Pulmonary Arrhythmia Ablation 40

HeartRhythm

MARCH 31, 2025

Although increasing evidence supports substrate-based ablation strategies targeting extra-PV sources, reliable endpoints during CA beyond pulmonary vein (PV) isolation are not well established. Recently, a novel dipole charge density mapping (DCDM) system was developed for CA of complex arrhythmias.

Pulmonary 40

Pulmonary Ablation Atrial Fibrillation Tachycardia 40

HeartRhythm

MARCH 31, 2025

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in adults, leading to significant cardiovascular complications such as ischemic stroke, heart failure, and myocardial infarction. Pulmonary vein isolation (PVI) is a well-established treatment for rhythm control in patients with AF.

Atrial Fibrillation 40

Atrial Fibrillation Pulmonary Myocardial Infarction Heart Failure 40

HeartRhythm

JANUARY 29, 2024

With the advent of self-expanding transcatheter valves that can be safely deployed into the native RVOT, it is now possible to avoid repeat cardiac operations to address progressive pulmonary valve dysfunction.

Pulmonary 40

Pulmonary Congenital Heart Disease Arrhythmia Congenital 40

Frontiers in Cardiovascular Medicine

JANUARY 31, 2024

Background Pulmonary vein isolation with wide antral ablation leads to better clinical outcomes for the treatment of atrial fibrillation, but the isolation lesion is invisible in conventional cryoballoon ablation. The primary outcome was a clinical recurrence of documented atrial arrhythmias for >30 s during the 1-year follow-up.

Atrial Fibrillation 64

Atrial Fibrillation Ablation Pulmonary Outcomes 64

HeartRhythm

APRIL 30, 2024

Animal studies suggest that catheter ablation-associated parasympathetic and sympathetic denervation could result in increased ventricular arrhythmias (VA). The impact of catheter ablation of atrial fibrillation on VA burden in humans has not been assessed.

Atrial Fibrillation 40

Atrial Fibrillation Arrhythmia Ablation Pulmonary 40

Journal of Cardiovascular Electrophysiology

DECEMBER 10, 2024

Objective We report the feasibility, safety, and clinical efficacy of focal monopolar PFA in patients with the origin of their atrial arrhythmia in the SVC. Conclusions In this patient cohort with SVC-triggered atrial arrhythmia, isolation using focal monopolar PFA was feasible, effective, and safe.

Arrhythmia 40

Arrhythmia Ablation Pulmonary Tachycardia 40

HeartRhythm

APRIL 30, 2024

Multiple randomized controlled trials (RCTs) have compared the efficacy of pulmonary vein isolation (PVI) adjunctive techniques with PVI alone in patients with persistent atrial fibrillation (AF).

Atrial Fibrillation 40

Atrial Fibrillation Pulmonary Arrhythmia 40

Circulation: Arrhythmia and Electrophysiology

JANUARY 29, 2024

Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:High-power short-duration ablation has shown impressive efficacy and safety for pulmonary vein isolation (PVI); however, initial efficacy results with very high power short-duration ablation were discouraging. No complications occurred.

Electrophysiology 76

Electrophysiology Atrial Fibrillation Pulmonary Arrhythmia 76

DAIC

APRIL 18, 2024

This forms the physiologic rationale for the accepted convention of a three-month blanking period, during which arrhythmia recurrences are presumed to be relatively benign and not indicative of treatment failure. However, this reasoning disregards valuable data regarding early arrhythmia recurrences and their potential significance.

Atrial Fibrillation 111

Atrial Fibrillation Ablation Heart Rhythm Article 111

Journal of Cardiovascular Electrophysiology

MARCH 17, 2025

Young adults had a higher proportion of FAT originating from the superior vena cava and pulmonary veins. After a mean follow-up of 47.2 months, FAT recurred in 57 patients.

Tachycardia 40

Tachycardia Ablation Outcomes Tricuspid 40

HeartRhythm

MARCH 31, 2025

A thirty-seven-year-old woman with a Taussig-Bing anomaly had a complex repair with placement of a conduit from the right ventricle (RV) to the pulmonary artery (PA) during childhood (Figure 1A-C show anatomy). MRI revealed delayed enhancement associated with the conduit anastomosis.

Anatomy 40

Anatomy Arrhythmia Tachycardia Pulmonary 40

Journal of Cardiovascular Electrophysiology

OCTOBER 19, 2023

Although the QDOT MICRO™ Catheter was mainly designed for pulmonary vein isolation (PVI) its versatility to treat atrial fibrillation (AF) and other types of arrhythmias was recently evaluated by the FAST and FURIOUS study series and other studies and will be presented in this article.

Arrhythmia 40

Arrhythmia Ablation Atrial Flutter Atrial Fibrillation 40

Dr. S. Venkatesan MD

APRIL 28, 2024

Both atria develop from a combination of the primitive atrium, sinus venous, and pulmonary veins.It Spatial relationship of sites for atrial fibrillation drivers and atrial tachycardia in patients with both arrhythmias July 2017 International Journal of Cardiology 248(3) AF begets AF. Let us see few factors. References Nil ,

Atrial Fibrillation 75

Atrial Fibrillation Bicuspid/Mitral Pulmonary Ablation 75

Circulation: Arrhythmia and Electrophysiology

NOVEMBER 3, 2023

Circulation: Arrhythmia and Electrophysiology, Volume 16, Issue 11 , Page e012043, November 1, 2023. BACKGROUND:In patients with persistent atrial fibrillation (PersAF), catheter ablation aiming for pulmonary vein isolation (PVI) is associated with moderate clinical effectiveness.

Atrial Fibrillation 40

Atrial Fibrillation Pulmonary Quality of Life Ablation 40

European Journal of Heart Failure

FEBRUARY 25, 2025

PVI, pulmonary vein isolation. Herein we describe the effects of catheter ablation on AF burden, arrhythmia recurrences, and ventricular function in end-stage HF. Overall, 97 patients received ablation; 66 patients (68%) underwent pulmonary vein isolation (PVI) and 31 patients (32%) were treated with PVI and additional ablation.

Atrial Fibrillation 40

Atrial Fibrillation Heart Failure Ablation Arrhythmia 40

HeartRhythm

MARCH 31, 2025

Identifying nearfield and farfield signals is critical to mapping and ablating cardiac arrhythmias. This assessment is qualitative, depending on the sharpness of electrograms. Electrogram peak frequency (PF) is hypothesized to be a quantitative measure of signal proximity.

Pulmonary 40

Pulmonary Arrhythmia Ablation 40

HeartRhythm

MARCH 31, 2025

Catheter ablation via pulmonary vein isolation (PVI) is first-line treatment for paroxysmal atrial fibrillation (pAF). It is unclear whether additional lesions with PVI using the novel pulsed field ablation (PFA) technique affects outcomes in this population.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Arrhythmia Pulmonary 40

DAIC

DECEMBER 29, 2023

Unlike paroxysmal AF, which describes symptoms that last for seven days or fewer, persistent AF is a sustained arrhythmia that lasts for more than a week 1. Early treatment of persistent AF can reduce the risk of blood clots, stroke, and heart failure, and may prevent the disease from becoming permanent.

Atrial Fibrillation 115

Atrial Fibrillation Ablation Atrial Flutter Blood Clot 115

HeartRhythm

NOVEMBER 21, 2024

2 BB area pacing defined using P-wave criteria has been associated with decreased atrial arrhythmia burden, recurrence, and de novo incidence compared with right atrial septal pacing and right atrial appendage pacing.3

Pulmonary 40

Pulmonary Atrial Fibrillation Arrhythmia 40

HeartRhythm

MARCH 31, 2025

Persistent atrial fibrillation (AF) ablation targeting extra-pulmonary vein drivers using various technologies has delivered varying results from no benefit to significant arrhythmia free survival.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pulmonary Technology 40

HeartRhythm

APRIL 30, 2024

The approach for recurrent persistent AF, beyond pulmonary vein isolation, remains contentious. Despite advances, catheter ablation success rates for persistent AF remain at 50-60%. Surgical maze procedures have demonstrated superior outcomes compared to catheter ablation.

Ablation 40

Ablation Arrhythmia Pulmonary Outcomes 40

HeartRhythm

MARCH 31, 2025

While pulmonary vein isolation (PVI) durability appears comparable between PFA and TA, the necessity of post-ablation remapping remains uncertain. Pulsed field ablation (PFA) is a promising new alternative to thermal ablation (TA) for atrial fibrillation (AF), improving safety and duration of procedure times.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Arrhythmia Pulmonary 40

HeartRhythm

MARCH 31, 2025

Pulsed field ablation (PFA) has emerged as a new ablation method for treating atrial fibrillation (AF) through pulmonary vein isolation (PVI).

Ablation 40

Ablation Atrial Fibrillation Arrhythmia Technology 40

Journal of Cardiovascular Electrophysiology

DECEMBER 7, 2023

Abstract Background The newly introduced nonthermal pulsed field ablation (PFA) is a promising technology to achieve fast pulmonary vein isolation (PVI) with high acute success rates and good safety features. Two tamponades occurred in the PFA while in VHPSD two pts suffered groin bleedings.

Ablation 40

Ablation Pulmonary Arrhythmia Atrial Fibrillation 40

Circulation: Arrhythmia and Electrophysiology

MARCH 21, 2025

Circulation: Arrhythmia and Electrophysiology, Ahead of Print.

Electrophysiology 40

Electrophysiology Atrial Fibrillation Arrhythmia Pulmonary 40

HeartRhythm

FEBRUARY 15, 2024

Pulmonary vein isolation (PVI) has been established as a cornerstone therapy for atrial fibrillation (AF). 1 Several studies have highlighted the significant role of non-pulmonary premature atrial complexes (non-PV PACs) in triggering AF/AT episodes.2,3

Arrhythmia 40

Arrhythmia Atrial Fibrillation Pulmonary Ablation 40